SRRK Scholar Rock, Inc.
Scholar Rock, Inc. (SRRK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 45% planned / 55% discretionary
Largest single sale: $6.2M.
Where they traded
Last open-market purchase: October 7, 2025 , by AKKARAJU SRINIVAS .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Peng Katie 3 fills | Director | Sell 10b5-1 | 5,446 | $53.88 | $293.4K | 36,759 −12.9% of holding | |
| FLIER JEFFREY S. 3 fills | Director | Sell 10b5-1 | 3,053 | $53.88 | $164.5K | 29,341 −9.4% of holding | |
| Reed Joshua 2 fills | Director | Sell 10b5-1 | 3,053 | $53.74 | $164.1K | 20,466 −13% of holding | |
| Burow Kristina 2 fills | Director | Sell 10b5-1 | 3,053 | $53.74 | $164.1K | 115,605 −2.6% of holding | |
| Gilman Michael 3 fills | Director | Sell 10b5-1 | 2,544 | $53.87 | $137.1K | 60,709 −4% of holding | |
| Hallal David | Chief Executive Officer | Sell | 30,615 | $49.57 | $1.5M | 1,639,034 −1.8% of holding | |
| Vaishnaw Akshay | President of R&D | Sell | 12,246 | $49.57 | $607.1K | 630,542 −1.9% of holding | |
| Sinha Vikas | Chief Financial Officer | Sell | 10,410 | $49.57 | $516.1K | 619,856 −1.7% of holding | |
| Woods Keith | Chief Operating Officer | Sell | 10,220 | $49.57 | $506.7K | 620,055 −1.6% of holding | |
| Qatanani Mo 3 fills | CHIEF SCIENTIFIC OFFICER | Sell 10b5-1 | 8,484 | $47.07 | $399.4K | 99,502 −7.9% of holding | |
| Ho Junlin | GENERAL COUNSEL | Sell | 9,580 | $46.53 | $445.7K | 241,545 −3.8% of holding | |
| Parlavecchio Caryn | CHRO | Sell | 9,035 | $46.53 | $420.4K | 169,087 −5.1% of holding | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 7,989 | $46.53 | $371.7K | 106,929 −7% of holding | |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 4,157 | $46.53 | $193.4K | 126,012 −3.2% of holding | |
| Qatanani Mo 2 fills | CHIEF SCIENTIFIC OFFICER | Sell 10b5-1 | 14,898 | $46.71 | $695.9K | 98,439 −13.1% of holding | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 8,406 | $44.48 | $373.9K | 100,558 −7.7% of holding | |
| Ho Junlin | GENERAL COUNSEL | Sell | 8,016 | $44.48 | $356.5K | 214,553 −3.6% of holding | |
| Parlavecchio Caryn | CHRO | Sell | 6,600 | $44.48 | $293.6K | 148,864 −4.2% of holding | |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 5,798 | $44.48 | $257.9K | 95,687 −5.7% of holding | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell 10b5-1 | 13,112 | $45.20 | $592.6K | 108,964 −10.7% of holding | |
| Hallal David | Chief Executive Officer | Sell | 57,450 | $42.70 | $2.5M | 1,541,645 −3.6% of holding | |
| Vaishnaw Akshay | President of R&D | Sell | 20,438 | $42.70 | $872.7K | 595,767 −3.3% of holding | |
| Sinha Vikas | Chief Financial Officer | Sell | 16,755 | $42.70 | $715.4K | 583,245 −2.8% of holding | |
| Woods Keith | Chief Operating Officer | Sell | 16,746 | $42.70 | $715.1K | 583,254 −2.8% of holding | |
| Peng Katie 2 fills | Director | Sell 10b5-1 | 1,006 | $44.09 | $44.4K | 33,188 −2.9% of holding | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell 10b5-1 | 136,462 | $45.21 | $6.2M | 108,964 −55.6% of holding | |
| AKKARAJU SRINIVAS 3 fills | Director | Buy | 29,599 | $39.92 | $1.2M | 530,038 | |
| AKKARAJU SRINIVAS 3 fills | Director | Buy | 113,025 | $38.65 | $4.4M | 500,439 | |
| AKKARAJU SRINIVAS 3 fills | Director | Buy | 387,414 | $37.27 | $14.4M | 387,414 | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,353 | $30.67 | $102.8K | 108,964 −3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.